Molecular Combing is an accurate and powerful technology for studying the kinetics of DNA replication.
Alterations in DNA replication represent a major source of genomic instability in precancerous lesions and play a central role in the development of cancer (carcinogenesis). The recent development of single-molecule approaches opens new approaches to understand these phenomena.
We have developed the Replication Combing Assay to monitor the kinetics of DNA replication. This experimental assay provides an unrivalled capability in the analysis of DNA replication during normal or abnormal cell division. The Replication Combing Assay can:
Our objective is to provide Molecular Combing technology for fundamental research on DNA (cytogenetics and replication) and for applications in cancer research.
Genomic Vision is committed to helping research laboratories implement Molecular Combing by providing a set of tools, installation and ongoing technical and application support.
Genomic Vision operates under a specific agreement, which includes discounts on products and assistance with implementing Molecular Combing in the laboratory.
The Replication Combing Assay (RCA)
The Replication Combing Assay is a unique approach that is well suited to test the efficacy of lead compounds by studying DNA replication in proliferating cancer cells and comparing the modes of action of drug candidates.
Dynamic changes to the genome structure and to the DNA replication program represent a major source of genomic instability in precancerous lesions and play a central role in the cancer process.
There are currently only a few genomics-based tools for drug validation and none of them target the kinetics of DNA replication. We have developed the Replication Combing Assay to monitor the kinetics of DNA replication during cell division in normal and pathological cells.
By using the test to evaluate the efficacy of anti-cancer molecules and to detect genomic instability, pharmaceutical companies will have access to a novel, high-performance approach for the development of new clinically active drugs.